Traders should monitor for preliminary data in H2 2026, which could drive significant volatility. The prior Phase 1/2 data provides some de-risking, but the Phase 2 readout is the key catalyst. Given the $55M market cap, positive data could lead to a multi-bagger, while negative data could severely impair the stock. Consider position sizing accordingly.
INKT drugs
INKT drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $10.51entry
- T+1 · 6mo ago +2.00%α +3.23% · $10.72
- T+5 · 6mo ago +4.09%α +4.81% · $10.94
- T+20 · 5mo ago +14.37%α +15.23% · $12.02
- T+60 · 3mo ago +4.19%α +0.60% · $10.95
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MiNK Therapeutics announced the initiation of a randomized Phase 2 trial (C-1300-02) evaluating its off-the-shelf iNKT cell therapy agenT-797 in patients with acute lung injury and hypoxemic respiratory failure. The study, conducted in partnership with First Lviv Medical Union and UNBROKEN Ukraine, targets a large unmet need with no approved therapies, and preliminary data are expected in H2 2026. For a $55M market cap clinical-stage biotech, this represents a significant pipeline catalyst with potential to unlock a new indication beyond oncology.
Key Facts
- Randomized Phase 2 trial (C-1300-02) initiated for agenT-797 in acute lung injury (ALI) with hypoxemic respiratory failure.
- Study is placebo-controlled, evaluating survival, ventilator-free days, and secondary infections; preliminary data expected H2 2026.
- AgenT-797 is an off-the-shelf allogeneic iNKT cell therapy, enabling rapid deployment in critical care without patient-specific manufacturing.
- Prior Phase 1/2 data (Hammond et al., Nat Comms) showed improved survival and reduced secondary infections in virally induced ARDS.
- Partnership with First Lviv Medical Union and UNBROKEN Ukraine provides access to a high-acuity patient population; U.S. sites being added.
- ALI/ARDS affects ~200,000 patients annually in the U.S. with no approved mortality-reducing therapies.
- MiNK market cap is ~$55M, making this a high-risk/high-reward catalyst for a small-cap biotech.
Financial Impact
No financial data provided; trial is early-stage with no revenue or deal value disclosed. Potential upside is binary based on H2 2026 data readout.
Risk Factors
- Clinical trial failure: Phase 2 may not replicate prior Phase 1/2 signals.
- Regulatory uncertainty: No approved therapies exist for ARDS; path to approval is unproven.
- Execution risk: Trial in Ukraine faces geopolitical and operational challenges.
- Cash runway: As a clinical-stage company, MiNK may need to raise capital before data readout.
- Competition: Other immune-modulating therapies in development for ARDS.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294797 |
Track record
21 reports on INKT
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers